Search the GHTC website

Global health R&D delivers for Ohio

US government investment in global health R&D has delivered

$165.5 million
to Ohio research institutions
2,200+ new jobs
for Ohio
Global health R&D at work in Ohio

Cincinnati Children’s Hospital Medical Center led early stage clinical trials of two Shigella vaccine candidates. Worldwide, Shigella causes more than 150 million cases of severe diarrhea and dysentery annually, including 500,000 cases in the United States, and kills more than 1 million people each year, most of whom are young children in low-income countries. Antibiotics are the standard treatment, but drug-resistant strains are emerging, and no vaccine is yet available.

  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Jobs created: Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See methodology for additional details.
  • Case study photo: PATH/Gabe Bienczycki